Polymorphisms of FAS and FAS ligand genes and risk of skin cancer

Journal of Dermatological Science

Volumn 58, Issue 1, 2010, Pages 78-80

  Qureshi, Abrar ^a   Nan, Hongmei ^a,b   Dyer, Michael ^a   Han, Jiali ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

FAS; Ligand; Polymorphism; Skin cancer

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

BASAL CELL CARCINOMA; CANCER CLASSIFICATION; CANCER RISK; CANCER SUSCEPTIBILITY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; LETTER; MELANOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD95; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; HAPLOTYPES; HUMANS; MELANOMA; POLYMORPHISM, GENETIC; RISK FACTORS; SKIN NEOPLASMS;

EID: 77950367670     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.01.003     Document Type: Letter

References (10)

1. Armstrong B.K., Kricker A., English D.R. Sun exposure and skin cancer. Australas J Dermatol 1997, 38(Suppl. 1):S1-S6.
2. Banerjee G., Gupta N., Kapoor A., Raman G. UV induced bystander signaling leading to apoptosis. Cancer Lett 2005, 223(2):275-284.
3. Aragane Y., Maeda A., Cui C.Y., Tezuka T., Kaneda Y., Schwarz T. Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo. J Invest Dermatol 2000, 115(6):1008-1014.
4. Erb P., Ji J., Wernli M., Kump E., Glaser A., Büchner S.A. Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett 2005, 100(1):68-72.
5. Huang Q.R., Morris D., Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997, 34(8-9):577-582.
6. Sibley K., Rollinson S., Allan J.M., Smith A.G., Law G.R., Roddam P.L., et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003, 63(15):4327-4330.
7. Wu J., Metz C., Xu X., Abe R., Gibson A.W., Edberg J.C., et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003, 170(1):132-138.
8. Han J., Colditz G.A., Hunter D.J. Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study. Int J Epidemiol 2006, 35(6):1514-1521.
9. Nelson H.H., Kelsey K.T., Bronson M.H., Mott L.A., Karagas M.R. Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2001, 10(7):809-810.
10. Li C., Larson D., Zhang Z., Liu Z., Strom S.S., Gershenwald J.E., et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 2006, 16(4):253-263.